American Journal of BioMedicine Volume 2, Issue 8, pages 1025-1037 September 2014
Yojirou Kishihara; Osamu Kawai; ArthurTakeuchi
Abstract
Systemic lupus erythematosus (SLE) is a systemic autoimmune and inflammatory disease characterized by the polyclonal activation of T and B lymphocytes, production of autoantibodies, and formation of immune complex. We measured the serum level of myeloperoxidase (MPO) in patients with SLE (n = 97) and in healthy controls (n = 88) and assessed the correlation between the serum myeloperoxidase (MPO) levels and established disease-activity indexes. All patient samples with SLE analyzed showed higher serum levels of MPO than healthy controls. Higher MPO levels were observed in SLE patients with increased C-reactive protein (P=0.001), as well as in those with highly active disease (P<0.005). Our concluded is that the associations between MPO and the disease variables of SLE patients support a role for MPO in the inflammatory process of the disease.
Keywords: Systemic lupus erythematosus; Myeloperoxidase; Immune complex; C-reactive protein
Limited Access HTML Full Text-PDF Feedback
References
1. Kotzin BL. Systemic lupus erythematosus. Cell 1996;14:303–306. [PubMed]
2. Cooper GS, Dooley MA, Treadwell EL, St Clair EW, Parks CG, Gilkeson GS. Hormonal, environmental, and infectious risk factors for developing systemic lupus erythematosus. Arthritis Rheum 1998; 41(10):1714-24. [PubMed]
3. Sadik CD, Kim ND, Luster AD. Neutrophils cascading their way to inflammation. Trends Immunol 2011; 32:452–460. [Abstract/Full-Text]
4. Amulic B, Cazalet C, Hayes GL, Metzler KD, Zychlinsky A. Neutrophil function: from mechanisms to disease. Annu. Rev. Immunol 2012; 30:459–489. [Abstract/Full-Text]
5. Houssiau FA. Management of lupus nephritis: an update. J Am Soc Nephrol 2004; 15(10): 2694-2704. [PubMed]
6. Granter J, Calvin MB, Westover JG, Wu Y, Lee T, Kim L, Frugier P. Expression of orphan receptor GPR15/BOB up-regulated in systemic lupus erythematous/crosstalk with pro-inflammatory cytokines. American Journal of BioMedicine 2014; 2: 870-886. [Abstract/Full-Text]
7. Mills JA. Systemic lupus erythematosus. N Engl J Med 1994;14:1871. [PubMed]
8. Pisetsky DS, Rönnblom L. Systemic lupus erythematosus: a matter of life and death. Arthritis Rheum 2009;14:1567–1570. [PubMed]
9. Christensen SR, Kashgarian M, Alexopoulou L, Flavell RA, Akira S, Shlomchik MJ. Toll-like receptor 9 controls anti-DNA autoantibody production in murine lupus. J Exp Med 2005;14:321–331. [PubMed]
10. Tao K, Fujii M, Tsukumo S, Maekawa Y, Kishihara K, Kimoto Y, Horiuchi T, Hisaeda H, Akira S, Kagami S, Yasutomo K. Genetic variations of Toll-like receptor 9 predispose to systemic lupus erythematosus in Japanese population. Ann Rheum Dis 2007;14:905–909. [PubMed]
11. Miyata M, Ito O, Kobayashi H, Sasajima T, Ohira H, Suzuki S, Kasukawa R. CpG-DNA derived from sera in systemic lupus erythematosus enhances ICAM-1 expression on endothelial cells. Ann Rheum Dis 2001;14:685–689. [PubMed]
12. Kessenbrock K, Dau T, Jenne DE. Tailor-made inflammation: how neutrophil serine proteases modulate the inflammatory response. J Mol Med (Berl) 2011;14:23–28. [PubMed]
13. Wong CK, Wong PT, Tam LS, Li EK, Chen DP, Lam CW. Activation profile of Toll-like receptors of peripheral blood lymphocytes in patients with systemic lupus erythematosus. Clin Exp Immunol 2010;14:11–22. [PubMed]
14. Klashman DJ, Martin RA, Martinez-Maza O, Stevens RH. In vitro regulation of B cell differentiation by interleukin-6 and soluble CD23 in systemic lupus erythematosus B cell subpopulations and antigen-induced normal B cells. Arthritis Rheum 1991;14:276–286. [PubMed]
15. Weckerle CE, Franek BS, Kelly JA, Kumabe M, Mikolaitis RA, Green SL, Utset TO, et. al. Network analysis of associations between serum interferon-α activity, autoantibodies, and clinical features in systemic lupus erythematosus. Arthritis Rheum 2011;14:1044–1053. [PubMed]
16. Boldron J, Caltabiano S, Debono SD, Thompson R, Scammells M, Westover R, Wu Y, Frugier P. Adhesion molecule expression trigger immune-mediated pathology in lupus-nephritis. American Journal of BioMedicine 2013;1:49–57. [Abstract/Full-Text]
17. Tsao BP. The genetics of human systemic lupus erythematosus. Trends Immunol 2003;24:595–602. [PubMed]
18. Croker JA, Kimberly RP. Genetics of susceptibility and severity in systemic lupus erythematosus. Curr Opin Rheumatol 2005;17:529–537. [PubMed]
19. Manderson AP, Botto M, Walport MJ. The role of complement in the development of systemic lupus erythematosus. Annu Rev Immunol 2004; 22:431–456. [PubMed]
20. Yu CY, Hauptmann G, Yang Y, Wu YL, Birmingham DJ, Rovin BH, Hebert LA. Complement deficiencies in human systemic lupus erythematosus (SLE) and SLE nephritis: epidemiology and pathogenesis. In: Tsokos GC (ed) Systemic lupus erythematosus: a companion to rheumatology. Elsevier, Philadelphia, 2007, pp 203–213.
21. Schur PH, Sandson J. Immunologic factors and clinical activity in systemic lupus erythematosus. N Engl J Med 1968; 278:533–538. [PubMed]
